| The Oxford classification of IgA nephropathy: rationale, clinicopathological correlations, and classification AWG of the International, IAN Network, DC Cattran, R Coppo, HT Cook, ... Kidney international 76 (5), 534-545, 2009 | 1201 | 2009 |
| The Oxford classification of IgA nephropathy: pathology definitions, correlations, and reproducibility AWG of the International, IAN Network, ISD Roberts, HT Cook, S Troyanov, ... Kidney international 76 (5), 546-556, 2009 | 975 | 2009 |
| Oxford classification of IgA nephropathy 2016: an update from the IgA nephropathy classification working group H Trimarchi, J Barratt, DC Cattran, HT Cook, R Coppo, M Haas, ZH Liu, ... Kidney international 91 (5), 1014-1021, 2017 | 950 | 2017 |
| IgA nephropathy J Barratt, J Feehally Journal of the American Society of Nephrology 16 (7), 2088-2097, 2005 | 709 | 2005 |
| Discovery of new risk loci for IgA nephropathy implicates genes involved in immunity against intestinal pathogens K Kiryluk, Y Li, F Scolari, S Sanna-Cherchi, M Choi, M Verbitsky, D Fasel, ... Nature genetics 46 (11), 1187-1196, 2014 | 634 | 2014 |
| Executive summary of the KDIGO 2021 guideline for the management of glomerular diseases BH Rovin, SG Adler, J Barratt, F Bridoux, KA Burdge, TM Chan, HT Cook, ... Kidney international 100 (4), 753-779, 2021 | 473 | 2021 |
| KDIGO 2021 clinical practice guideline for the management of glomerular diseases BH Rovin, SG Adler, J Barratt, F Bridoux, KA Burdge, TM Chan, HT Cook, ... Kidney international 100 (4), S1-S276, 2021 | 453 | 2021 |
| Validation of the Oxford classification of IgA nephropathy in cohorts with different presentations and treatments R Coppo, S Troyanov, S Bellur, D Cattran, HT Cook, J Feehally, ... Kidney international 86 (4), 828-836, 2014 | 444 | 2014 |
| Mesangial IgA1 in IgA nephropathy exhibits aberrant O-glycosylation: observations in three patients AC Allen, EM Bailey, PEC Brenchley, KS Buck, J Barratt, J Feehally Kidney international 60 (3), 969-973, 2001 | 382 | 2001 |
| Targeted-release budesonide versus placebo in patients with IgA nephropathy (NEFIGAN): a double-blind, randomised, placebo-controlled phase 2b trial BC Fellström, J Barratt, H Cook, R Coppo, J Feehally, JW de Fijter, ... The Lancet 389 (10084), 2117-2127, 2017 | 358 | 2017 |
| A multicenter study of the predictive value of crescents in IgA nephropathy M Haas, JC Verhave, ZH Liu, CE Alpers, J Barratt, JU Becker, D Cattran, ... Journal of the American Society of Nephrology 28 (2), 691-701, 2017 | 293 | 2017 |
| Urine proteomics: the present and future of measuring urinary protein components in disease J Barratt, P Topham Cmaj 177 (4), 361-368, 2007 | 291 | 2007 |
| Treatment of IgA nephropathy J Barratt, J Feehally Kidney international 69 (11), 1934-1938, 2006 | 282 | 2006 |
| Management and treatment of glomerular diseases (part 1): conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference J Floege, SJ Barbour, DC Cattran, JJ Hogan, PH Nachman, SCW Tang, ... Kidney international 95 (2), 268-280, 2019 | 275 | 2019 |
| The MEST score provides earlier risk prediction in lgA nephropathy SJ Barbour, G Espino-Hernandez, HN Reich, R Coppo, ISD Roberts, ... Kidney international 89 (1), 167-175, 2016 | 271 | 2016 |
| Pathogenesis of IgA nephropathy J Barratt, J Feehally, AC Smith Seminars in nephrology 24 (3), 197-217, 2004 | 241 | 2004 |
| An update on the pathogenesis and treatment of IgA nephropathy JK Boyd, CK Cheung, K Molyneux, J Feehally, J Barratt Kidney international 81 (9), 833-843, 2012 | 229 | 2012 |
| The Oxford IgA nephropathy clinicopathological classification is valid for children as well as adults R Coppo, S Troyanov, R Camilla, RJ Hogg, DC Cattran, HT Cook, ... Kidney international 77 (10), 921-927, 2010 | 204 | 2010 |
| Proteinuria reduction as a surrogate end point in trials of IgA nephropathy A Thompson, K Carroll, LA Inker, J Floege, V Perkovic, S Boyer-Suavet, ... Clinical Journal of the American Society of Nephrology 14 (3), 469-481, 2019 | 195 | 2019 |
| Management and treatment of glomerular diseases (part 2): conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference BH Rovin, DJ Caster, DC Cattran, KL Gibson, JJ Hogan, MJ Moeller, ... Kidney international 95 (2), 281-295, 2019 | 184 | 2019 |
